<DOC>
	<DOCNO>NCT01513590</DOCNO>
	<brief_summary>This trial conduct Africa , Asia Europe . The aim trial compare efficacy safety insulin degludec/insulin aspart BIAsp 30 ( biphasic insulin aspart 30 ) insulin na誰ve subject type 2 diabetes .</brief_summary>
	<brief_title>A Trial Comparing Efficacy Safety Insulin Degludec/Insulin Aspart BIAsp 30 Insulin na誰ve Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<criteria>Informed consent obtain trialrelated activity . ( Trialrelated activity procedure would perform normal management subject ) Type 2 diabetes mellitus ( diagnose clinically ) least 24 week prior screen Current treatment : metformin monotherapy metformin combination one follow oral antidiabetic drug ( OADs ) : insulin secretagogue ( sulfonylurea glinide ) , dipeptidyl peptidase IV ( DPPIV ) inhibitor , alphaglucosidase inhibitor least 12 week prior randomisation ( Visit 2 ) minimum dos state : Metformin : alone combination ( include fix combination ) 1500 mg daily , maximum tolerate dose ( least 1000 mg daily ) , Insulin secretagogue ( sulphonylurea glinide ) : minimum half daily maximum dose accord local labelling , DPPIV inhibitor : minimum 100 mg daily accord local labelling , Alphaglucosidaseinhibitors : minimum half daily maximum dose maximum tolerate dose Insulin na誰ve subject ; allow : Previous short term insulin treatment 14 day Insulin na誰ve subject ; allow : Treatment hospitalization gestational diabetes allow period longer 14 day ) HbA1c ( glycosylated haemoglobin ) 7.010.0 % ( inclusive ) central laboratory analysis Body mass index ( BMI ) equal 40.0 kg/m^2 Treatment thiazolidinediones ( TZDs ) glucagon like peptide 1 ( GLP1 ) receptor agonist within 12 week prior visit 1 ( screen ) Anticipated change concomitant medication know interfere significantly glucose metabolism , systemic corticosteroid , betablockers MAO inhibitor Anticipated significant lifestyle change trial accord discretion trial physician , e.g . shift work ( include permanent night/evening shift worker ) , well highly variable eat habit Cardiovascular disease , within last 24 week prior trial start , define : stroke ; decompensated heart failure NYHA ( New York Heart Association ) class III IV ; myocardial infarction ; unstable angina pectoris ; coronary arterial bypass graft angioplasty Any clinically significant disease disorder , except condition associate type 2 diabetes , trial physician 's opinion could interfere result trial Previous participation trial . Participation define randomise . Rescreening screen failure allow within limit recruitment period Known suspect hypersensitivity trial product relate product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>